Financial Daily from THE HINDU group of publications
Saturday, Aug 07, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Marketing - Courts/Legal Issues
Industry & Economy - Pharmaceuticals


SC notices on cancer drug marketing rights

C.R. Sukumar

Hyderabad , Aug. 6

THE debate over the issue of exclusive marketing rights (EMRs) to overseas pharmaceutical company took a fresh turn on Friday with the Supreme Court issuing notices to the Central Government, Drug Controller General of India and the Controller General of Patents and National Pharmaceutical Pricing Authority following a petition filed by the Cancer Patients Aid Association (CPAA).

CPAA had moved the court alleging that the price of a widely-used cancer fighting drug would go out of the patients' reach with the granting of EMR in favour of the Swiss drug major Novartis.

The Supreme Court bench comprising Justice Y.K. Sabharwal and Justice D.M. Dharmadhikari issued notice to Novartis, while posting the case for hearing after four weeks. The court also directed the petitioners to file an affidavit on the status of the cases filed against EMR to Novartis in other courts as well.

According to the industry sources, "This could lead to the transfer of all the petitions filed against granting of EMR to a single designated court. At present, several petitions are under various stages of hearing at courts across the country."

The petitioner challenged the grant of EMR to Novartis for the drug Gleevec. The drug contains a crystalline form of the compound imatinib meyslate used for treating chronic myeloid leukaemia. The EMR blocks duplication and sale of the drug by any company other than Novartis for five years.

The petitioners submitted to the Supreme Court that following the grant of EMR to Novartis, the price of the drug would go up to Rs 1.2 lakh from Rs 4,000 at which the drug was made available to CPAA by Indian pharmaceutical companies.

Welcoming the Supreme Court orders, a senior official of a city-based pharmaceutical company told Business Line that though the judgement on the petition was pending, moving all the cases to one designated court would expedite the issue and find an early solution to the problem.

"We view that granting of EMR violates the provisions of right to health by way of denying access to medicines."

More Stories on : Courts/Legal Issues | Pharmaceuticals | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
GD Foods to enter ready-to-eat segment


Motorola ties up with EMI Music to push E398 mobile
`It's time to tap rural goldmine'
SC notices on cancer drug marketing rights
Fiat set to launch new campaign this month — No more high-decibel endorsements
Everest looks to scale new heights
1.66 million new cell customers in July
Pantaloon aims to double turnover in 2004-05
Big Four audit firms in bid for aMap testing
ITC travel arm brings out guidebook for tourists
Tata Motors CV sales to exceed sector's
A touch of glitter



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line